Trial · NCT06588699
Digoxin In NASH (CODIN)
NCT06588699, Phase 2, Recruiting, Yale University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Digoxin In NASH (CODIN). Trials, record NCT06588699. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06588699
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Digoxin In NASH (CODIN)
- NCT number
- NCT06588699
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 144 participants, estimated
- Lead sponsor
- Yale University
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash, MASH With Fibrosis, MASLD, Fatty Liver Disease, Fatty Liver Disease, Nonalcoholic
- Interventions
- Digoxin, Placebo
- First posted
- 2024-09-19
- Last updated
- 2026-05-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Resolution of nonalcoholic steatohepatitis (NASH) without worsening of fibrosis | 24 weeks | Proportion of participants who achieve resolution of NASH (defined by the NASH Clinical research network \[CRN\] as a score of 0-1 for inflammation, 0 for hepatocyte ballooning, and any value for steatosis) with no worsening of fibrosis (yes/no). |
| Secondary | Improvement in liver fibrosis without worsening of NASH | 24 weeks | Proportion of participants with improvement in liver fibrosis by ≥ 1 stage with no worsening of NASH (yes/no). Worsening of NASH is defined as ≥ 1 increase in lobular inflammation or hepatocyte ballooning according to criteria by the NASH clinical research network (NASH CRN) |
| Secondary | Improvement in NAS without worsening of fibrosis | 24 weeks | Proportion of participants with improvement in nonalcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 2 with no worsening of fibrosis after 24 weeks (yes/no) |
| Secondary | Change in enhanced liver fibrosis (ELF) score | 24 weeks | Change in Enhanced Liver Fibrosis (ELF) score. |
| Secondary | Change in alanine aminotransferase (ALT) | 24 weeks | Change in serum alanine aminotransferase (ALT) concentration (pg/ml) |
| Secondary | Change in aspartate aminotransferase (AST) | 24 weeks | Change in serum aspartate aminotransferase (AST) concentration (pg/ml) |
| Secondary | Change in gamma glutamyl transferase (GGT) | 24 weeks | Change in serum gamma glutamyl transferase (GGT) concentration (pg/ml) |
| Secondary | Change in liver stiffness measure (LSM) and controlled attenuation parameter (CAP) | 24 weeks | Change in liver stiffness measure (LSM) and controlled attenuation parameter (CAP) from baseline as measured by transient elastography. |
| Secondary | Change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) | 24 weeks | Change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) |
| Secondary | Change in Magnetic resonance elastography (MRE) | 24 weeks | Change from baseline in magnetic resonance elastography (MRE) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK134624 | Oral digoxin for the treatment of NASH | BANINI, BUBU AMA | YALE UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2024 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06588699
GET https://conductscience.org/api/trials/v1/NCT06588699/registered